About

2D Biologics: Redefining the Future of Cancer Treatment

Co-founded by Dr. Primal de Lanerolle and David Downs, MBA, 2D Biologics is a pioneering pharmaceutical startup at the cutting edge of cancer therapeutics. We are developing a first-in-class cancer drug that targets a structural vulnerability common to over 85% of solid tumors—including prostate and breast cancers—regardless of genetic profile.

Breakthrough Discovery:
In preclinical studies, our drug has demonstrated powerful tumor-killing effects with no significant short-term side effects and has shown synergistic potential with existing cancer therapies, amplifying their effectiveness. This platform approach could unlock a new standard of care across a wide range of solid tumors. 

Strategic Vision:
We are currently focused on fundraising and building strategic partnerships to accelerate development.

Market Opportunity:
Based on comparable biotech valuation models, our estimated market valuation at FDA Step 2 is $57 million for primary-use applications, to $1.7 billion for multi-use applications, positioning 2D Biologics as a major player in next-generation oncology.

🔗 Discover how 2D Biologics is redefining cancer treatment:
2D Biologics Presentation